Literature DB >> 15877738

Chimaerism analyses and subsequent immunological intervention after stem cell transplantation in patients with juvenile myelomonocytic leukaemia.

Ayami Yoshimi1, Charlotte M Niemeyer, Viktoria Bohmer, Ulrich Duffner, Brigitte Strahm, Hermann Kreyenberg, Dagmar Dilloo, Felix Zintl, Alexander Claviez, Willi Wössmann, Bernhard Kremens, Wolfgang Holter, Dietrich Niethammer, James F Beck, Udo Kontny, Peter Nöllke, Thomas Klingebiel, Peter Bader.   

Abstract

Chimaerism analysis was performed by polymerase chain reaction amplification of short-tandem repeat markers in 30 children following haematopoietic stem cell transplantation for juvenile myelomonocytic leukaemia (JMML). Fourteen patients always had complete chimaerism (CC); one of them relapsed after the discontinuation of the study and 13 continued in complete remission (CR). Mixed chimaerism (MC) was noted in 16 patients. Of those 12 patients demonstrated increasing MC (i-MC); 10 relapsed and two achieved CC following discontinuation of immunosuppressive therapy (IST). Four other patients demonstrating only transient MC are alive in CR. MC with up to 20% of autologous cells could be successfully eradicated without induction of severe graft-versus-host disease when IST was reduced or discontinued directly after the first demonstration of MC. At the same time, MC with up to 10% of autologous cells could disappear without intervention. The interval between MC and relapse ranged from 0-320 d (median 38 d). Donor leucocyte infusion was given to six patients with i-MC, but only one patient responded. Peripheral blood seems as valuable as bone marrow for chimaerism studies. In conclusion, serial quantitative chimaerism studies can identify patients with i-MC who are at high risk for relapse of JMML. Immediate withdrawal of IST is advised in these patients.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15877738     DOI: 10.1111/j.1365-2141.2005.05489.x

Source DB:  PubMed          Journal:  Br J Haematol        ISSN: 0007-1048            Impact factor:   6.998


  12 in total

1.  HLA-identical umbilical cord blood transplantation from a sibling donor in juvenile myelomonocytic leukemia.

Authors:  Andrica C H de Vries; Robbert G M Bredius; Arjan C Lankester; Marc Bierings; Monika Trebo; Petr Sedlacek; Charlotte M Niemeyer; Marco Zecca; Franco Locatelli; Marry M van den Heuvel-Eibrink
Journal:  Haematologica       Date:  2008-12-23       Impact factor: 9.941

2.  Criteria for evaluating response and outcome in clinical trials for children with juvenile myelomonocytic leukemia.

Authors:  Charlotte M Niemeyer; Mignon L Loh; Annamaria Cseh; Todd Cooper; Christopher C Dvorak; Rebecca Chan; Blanca Xicoy; Ulrich Germing; Seiji Kojima; Atsushi Manabe; Michael Dworzak; Barbara De Moerloose; Jan Starý; Owen P Smith; Riccardo Masetti; Albert Catala; Eva Bergstraesser; Marek Ussowicz; Oskana Fabri; André Baruchel; Hélène Cavé; Michel Zwaan; Franco Locatelli; Henrik Hasle; Marry M van den Heuvel-Eibrink; Christian Flotho; Ayami Yoshimi
Journal:  Haematologica       Date:  2015-01       Impact factor: 9.941

Review 3.  RAS diseases in children.

Authors:  Charlotte M Niemeyer
Journal:  Haematologica       Date:  2014-11       Impact factor: 9.941

Review 4.  Current management of juvenile myelomonocytic leukemia and the impact of RAS mutations.

Authors:  Nao Yoshida; Sayoko Doisaki; Seiji Kojima
Journal:  Paediatr Drugs       Date:  2012-06-01       Impact factor: 3.022

5.  Transplantation for juvenile myelomonocytic leukemia: a retrospective study of 30 children treated with a regimen of busulfan, fludarabine, and melphalan.

Authors:  Miharu Yabe; Yoshitoshi Ohtsuka; Kenichiro Watanabe; Jiro Inagaki; Nao Yoshida; Kazuo Sakashita; Harumi Kakuda; Hiromasa Yabe; Hidemitsu Kurosawa; Kazuko Kudo; Atsushi Manabe
Journal:  Int J Hematol       Date:  2014-12-11       Impact factor: 2.490

6.  Donor Killer Immunoglobulin Receptor Gene Content and Ligand Matching and Outcomes of Pediatric Patients with Juvenile Myelomonocytic Leukemia Following Unrelated Donor Transplantation.

Authors:  Hemalatha G Rangarajan; Marcelo S F Pereira; Ruta Brazauskas; Andrew St Martin; Ashleigh Kussman; Ezgi Elmas; Michael R Verneris; Shahinaz M Gadalla; Steven G E Marsh; Sophie Paczesny; Stephen R Spellman; Stephanie J Lee; Dean A Lee
Journal:  Transplant Cell Ther       Date:  2021-08-15

7.  Development of an allele-specific minimal residual disease assay for patients with juvenile myelomonocytic leukemia.

Authors:  Sophie Archambeault; Nikki J Flores; Ayami Yoshimi; Christian P Kratz; Miriam Reising; Alexandra Fischer; Peter Noellke; Franco Locatelli; Petr Sedlacek; Christian Flotho; Marco Zecca; Peter D Emanuel; Robert P Castleberry; Charlotte M Niemeyer; Peter Bader; Mignon L Loh
Journal:  Blood       Date:  2007-11-13       Impact factor: 22.113

Review 8.  Juvenile myelomonocytic leukemia: epidemiology, etiopathogenesis, diagnosis, and management considerations.

Authors:  Ayami Yoshimi; Seiji Kojima; Naoto Hirano
Journal:  Paediatr Drugs       Date:  2010       Impact factor: 3.022

9.  A pediatric case of systemic lupus erythematosus developed 10 years after cord blood transplantation for juvenile myelomonocytic leukemia.

Authors:  Masayuki Nagasawa; Yuki Aoki
Journal:  Case Rep Transplant       Date:  2012-12-10

Review 10.  Juvenile myelomonocytic leukemia: molecular pathogenesis informs current approaches to therapy and hematopoietic cell transplantation.

Authors:  Christopher C Dvorak; Mignon L Loh
Journal:  Front Pediatr       Date:  2014-03-28       Impact factor: 3.418

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.